Latest news with #TEVA
Yahoo
29-05-2025
- Business
- Yahoo
Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25. Teva Pharma is an Israeli pharmaceutical company best known as one of the world's largest manufacturers of generic drugs. In addition to generics, the company sells branded medicines and active pharmaceutical ingredients (APIs), offers contract manufacturing services, and operates an out-licensing platform through its affiliated company, Medis. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. The Truist analyst believes the company's strategy of building a portfolio of high-margin branded products while maintaining its core focus on generics is a key strength of its business model. This dual approach is expected to support sustainable and profitable growth in the years ahead. The company has recently launched a $700 million cost-cutting initiative aimed at enhancing operational efficiency by reducing headcount and external spending. The analyst believes that this program will support margin improvement and help the company achieve its target of a 30% operating margin by 2027. As a result of Teva's continued focus on debt and cost reduction, as well as profitable growth, credit rating agencies Moody's and Fitch upgraded the company's corporate credit rating on May 15 and 20, respectively. While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408
Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of celiac disease in patients adhering to a gluten-free diet. TEV-53408 is an anti-IL-15 monoclonal antibody designed to inhibit interleukin-15, a cytokine implicated in the immune response that leads to intestinal damage in celiac disease. The drug is currently being evaluated in a Phase 2a clinical trial to assess its efficacy and safety in adults with the condition. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. The FDA's Fast Track process is intended to accelerate the development and review of drugs that address serious conditions and unmet medical needs. Celiac disease, an autoimmune disorder triggered by gluten, affects about 1% of the global population. Despite strict adherence to a gluten-free diet, the only current treatment many patients continue to experience debilitating symptoms due to accidental gluten exposure. Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s Executive Vice President and Chief Medical Officer, Dr. Eric Hughes, highlighted that this designation reflects both the promise of TEV-53408 and the urgent need for new therapeutic options. The development of TEV-53408 underscores Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s commitment to advancing innovative treatments for chronic autoimmune diseases like celiac disease. While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408
Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of celiac disease in patients adhering to a gluten-free diet. TEV-53408 is an anti-IL-15 monoclonal antibody designed to inhibit interleukin-15, a cytokine implicated in the immune response that leads to intestinal damage in celiac disease. The drug is currently being evaluated in a Phase 2a clinical trial to assess its efficacy and safety in adults with the condition. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. The FDA's Fast Track process is intended to accelerate the development and review of drugs that address serious conditions and unmet medical needs. Celiac disease, an autoimmune disorder triggered by gluten, affects about 1% of the global population. Despite strict adherence to a gluten-free diet, the only current treatment many patients continue to experience debilitating symptoms due to accidental gluten exposure. Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s Executive Vice President and Chief Medical Officer, Dr. Eric Hughes, highlighted that this designation reflects both the promise of TEV-53408 and the urgent need for new therapeutic options. The development of TEV-53408 underscores Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s commitment to advancing innovative treatments for chronic autoimmune diseases like celiac disease. While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming investor conferences in June as follows: Jefferies Global Healthcare ConferenceChris Fox, EVP U.S. Commercial and Dr. Eric Hughes, EVP Global R&D and Chief Medical OfficerWednesday, June 4, 2025, at 9:20 am ET Goldman Sachs 46th Annual Global Healthcare ConferenceRichard Francis, President & CEOTuesday, June 10, 2025, at 8:00 am ET To access a live webcast of the presentation, visit Teva's Investor Relations website at An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we're already working to address it. To learn more about how Teva is all in for better health, visit Cautionary Note Regarding Forward-Looking Statements This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Yahoo
28-05-2025
- Business
- Yahoo
Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408
Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of celiac disease in patients adhering to a gluten-free diet. TEV-53408 is an anti-IL-15 monoclonal antibody designed to inhibit interleukin-15, a cytokine implicated in the immune response that leads to intestinal damage in celiac disease. The drug is currently being evaluated in a Phase 2a clinical trial to assess its efficacy and safety in adults with the condition. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. The FDA's Fast Track process is intended to accelerate the development and review of drugs that address serious conditions and unmet medical needs. Celiac disease, an autoimmune disorder triggered by gluten, affects about 1% of the global population. Despite strict adherence to a gluten-free diet, the only current treatment many patients continue to experience debilitating symptoms due to accidental gluten exposure. Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s Executive Vice President and Chief Medical Officer, Dr. Eric Hughes, highlighted that this designation reflects both the promise of TEV-53408 and the urgent need for new therapeutic options. The development of TEV-53408 underscores Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s commitment to advancing innovative treatments for chronic autoimmune diseases like celiac disease. While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
